Philip S. Tsao, PhD
Publication Details
-
Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.
PLoS One. 2008; (7): e2609
Recently, the type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling and imaging studies of a murine model of type 2 diabetes, the C57BL/KLS-lepr(db)/lepr(db) (db/db) mouse.
Help